Oblon D J, Paul S, Yankee R
Bone Marrow Transplant Program, Roger Williams Medical Center, and Department of Medicine, Brown University School of Medicine, Providence, Rhode Island 02908, USA.
Bone Marrow Transplant. 1997 Sep;20(5):421-3. doi: 10.1038/sj.bmt.1700905.
Successful allogeneic hematopoietic transplants require conditioning regimens with sufficient immunosuppression to allow acceptance of the allograft. Cyclophosphamide, in combination either with TBI or with chemotherapeutic drugs, is the keystone of commonly used regimens. The toxicities of TBI and tumor resistance to cyclophosphamide create a niche for alternative, chemotherapy-based conditioning regimens. We report successful allogeneic stem cell transplantation after an ifosfamide-based regimen with ifosfamide 20 g/m2, carboplatin 1.8 g/m2 and etoposide 3 g/m2 (ICE) in divided doses over 6 days. Engraftment was prompt with neutrophils > or = 20 x 10(9)/l on day +10 and platelets > 20 x 10(9)/l on day +18. Engraftment of donor cells was documented by chromosome analysis and by VNTR analysis. An ifosfamide-based regimen provides sufficient immunosuppression for hematopoietic allograft acceptance in the absence of cyclophosphamide or of TBI.
成功的异基因造血移植需要进行具有足够免疫抑制作用的预处理方案,以允许接受同种异体移植物。环磷酰胺与全身照射(TBI)或化疗药物联合使用,是常用预处理方案的关键。TBI的毒性以及肿瘤对环磷酰胺的耐药性为基于化疗的替代预处理方案创造了空间。我们报告了在基于异环磷酰胺的预处理方案后成功进行的异基因干细胞移植,该方案为异环磷酰胺20 g/m²、卡铂1.8 g/m²和依托泊苷3 g/m²(ICE),分剂量在6天内给予。在第+10天中性粒细胞≥20×10⁹/L,第+18天血小板>20×10⁹/L时迅速实现植入。通过染色体分析和可变数目串联重复序列(VNTR)分析记录了供体细胞的植入情况。在没有环磷酰胺或TBI的情况下,基于异环磷酰胺的预处理方案为接受造血同种异体移植物提供了足够的免疫抑制作用。